Advancing Heart Failure Treatment: The Role of Multipoint Pacing in Cardiac Resynchronization Therapy

Cardiac resynchronization therapy (CRT) with biventricular pacing is a standard therapy for patients with heart failure, reduced ejection fraction, and electrical dyssynchrony. However, approximately 30% of patients do not respond to CRT. Multipoint pacing (MPP) has emerged as an innovative strategy that paces multiple left ventricular sites to achieve more comprehensive resynchronization. This review explores the evolution of MPP, including the underlying scientific rationale, clinical evidence from key trials, technological considerations of quadripolar leads and programmability, patient selection criteria, optimization strategies, and future directions. Early feasibility studies demonstrated acute hemodynamic improvements with MPP. Larger trials have shown superior outcomes with MPP compared to conventional biventricular pacing, including increased CRT response rates, reduced hospitalizations, and improved ejection fraction and reverse remodeling. However, recent multicenter trials found no significant differences between the population's MPP and biventricular pacing. Ongoing research aims to refine patient selection for MPP and optimize lead positioning and programming configurations to maximize benefits. As technological capabilities expand, MPP promises to provide tailored, physiological pacing therapies that may enhance outcomes for heart failure patients requiring CRT. This comprehensive review examines the various aspects of MPP, including its scientific foundation, clinical evidence, technological considerations, impact on patient quality of life, and future implications. By critically assessing the current literature and identifying gaps in knowledge, we aim to provide a thorough understanding of MPP’s role in the evolving landscape of heart failure management.